Showing results (41-50 of 81) with videos related to
Sort By:
Pageof 9
Radiation Oncology (London, England)|April 12, 2011
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local controlMichelle A Stinauer, Brian D Kavanagh, Tracey E Schefter, et al.Journal of Strength and Conditioning Research|December 30, 2006
Determination of functional strength imbalance of the lower extremitiesRobert U Newton, Aimee Gerber, Sophia Nimphius, et al.Journal of Strength and Conditioning Research|February 17, 2016
The Impact of Competitive Trait Anxiety on Collegiate Powerlifting PerformanceLawrence W Judge, Leslie J Urbina, Donald L Hoover, et al.Biology Open|December 6, 2012
ABT-737 synergizes with Bortezomib to kill melanoma cellsSteven N Reuland, Nathaniel B Goldstein, Katie A Partyka, et al.Nuclear Medicine Communications|October 7, 2015
Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanomaRonald J Schmitt, Sarah M Kreidler, Deborah H Glueck, et al.European Journal of Cancer (Oxford, England : 1990)|June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinibKarl Lewis, Axel Hauschild, James Larkin, et al.Frontiers in Immunology|November 30, 2019
Assessing the Correlation Between Disease Severity Indices and Quality of Life Measurement Tools in PemphigusRebecca L Krain, Carolyn J Kushner, Meera Tarazi, et al.JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical TrialAmy McMichael, Mona Shahriari, Linda Stein Gold, et al.JAMA Dermatology|June 25, 2025
Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical TrialAndrew Alexis, Amy McMichael, Jennifer Soung, et al.American Journal of Surgery|December 13, 2006
Size of sentinel node metastases predicts other nodal disease and survival in malignant melanomaNathan W Pearlman, Martin D McCarter, Matthew Frank, et al.Pageof 9